Cardionate capsules 250mg, No. 40

• Reduced performance; mental and physical (including athletes) overload.

• As part of complex therapy: ischemic heart disease (exertional angina), chronic heart failure, cardialgia against the background of dyshormonal myocardial dystrophy.

• As part of complex therapy: cerebrovascular accident (ischemic stroke, chronic cerebrovascular insufficiency).

• Withdrawal symptoms in chronic alcoholism (as part of complex specific therapy).

Inside. The capsules should be swallowed whole, washed down with water.
In view of the possible development of an exciting effect, the drug is recommended to be used in the first half of the day.

Reduced performance, mental and physical overload - 500 mg (2 capsules) 2 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2 - 3 weeks.

Athletes - 500 mg - 1.0 g (2 - 4 capsules) 2 times a day before training. The duration of the course in the preparatory period of training is 14 - 21 days, during the competition period - 10 - 14 days.

Ischemic heart disease (exertional angina), chronic heart failure - 500 mg - 1.0 g (2 - 4 capsules) per day, using the entire dose at once or dividing it into 2 doses. The course of treatment is 4-6 weeks.

Cardialgia with dyshormonal myocardial dystrophy - 250 mg 2 times a day. The course of treatment is 12 days.

Cerebral circulation disorder.
In case of ischemic stroke - after the end of the 10-day course of therapy with the injectable form of CardionatЃ, the patient is transferred to taking the drug orally in capsules of 500 mg - 1.0 g (2 - 4 capsules) per day, taking the entire dose at once or dividing it into 2 doses. The general course of treatment is 4-6 weeks. For chronic cerebrovascular insufficiency - 500 mg (2 capsules) per day. The course of treatment is 2 - 3 weeks. The need for repeated courses of treatment (2-3 times a year) is determined by the doctor.

Withdrawal symptoms in chronic alcoholism - 500 mg (2 capsules) 4 times a day. The course of treatment is 7-10 days.

For one capsule:
Active ingredient
Meldonium dihydrate (trimethylhydrazinium propionate dihydrate) in terms of dihydrate without adsorbed moisture - 250 mg.
Excipients
Potato starch 13.3 mg. colloidal silicon dioxide (aerosil) 5.7 mg. calcium stearate 2.7 mg: capsule (gelatin, titanium dioxide).

Hypersensitivity to the main and / or auxiliary components of the drug; increased intracranial pressure (with impaired venous outflow and intracranial tumors); pregnancy; breastfeeding period; age up to 18 years (efficacy and safety have not been established).

Carefully

Chronic liver and / or kidney disease (due to insufficient data).

International non-proprietary name

Meldonium

Composition

For one capsule:
Active ingredient
Meldonium dihydrate (trimethylhydrazinium propionate dihydrate) in terms of dihydrate without adsorbed moisture - 250 mg.
Excipients
Potato starch 13.3 mg. colloidal silicon dioxide (aerosil) 5.7 mg. calcium stearate 2.7 mg: capsule (gelatin, titanium dioxide).

Description

White hard gelatin capsules No. 1. The contents of the capsules are a white or almost white crystalline powder with a faint odor. The powder is hygroscopic, clumping is allowed.

Pharmacotherapeutic group

Metabolic agent.

Pharmacological properties

Pharmacodynamics
A synthetic analogue of gamma-butyrobetaine, inhibits gamma-butyrobetaine hydroxylase, reduces the synthesis of carnitine and the transport of long-chain fatty acids through the cell membranes, prevents the accumulation of activated forms of unoxidized fatty acids in cells - derivatives of acylcarnitine and acyl coenzyme A. , which has vasodilating properties. Under conditions of ischemia, meldonium restores the balance of the processes of oxygen delivery and its consumption in cells, prevents a violation of the transport of adenosine triphosphate (ATP): at the same time, it activates glycolysis, which proceeds without additional oxygen consumption.

The mechanism of action determines the variety of pharmacological effects of meldonium: increased efficiency, reduced symptoms of mental and physical stress, activation of immunity, cardioprotective effect. In the case of acute ischemic myocardial damage, it slows down the formation of a necrotic zone and shortens the rehabilitation period. In case of heart failure, it increases myocardial contractility, increases exercise tolerance: reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus, promotes blood redistribution in favor of the ischemic area.

Characterized by a tonic effect on the central nervous system, the elimination of functional disorders of the autonomic division of the nervous system in withdrawal syndrome in patients with chronic alcoholism.

Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract, bioavailability - 78%. The maximum concentration in blood plasma is reached after 1-2 hours. It is metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. The half-life depends on the dose and is 3-6 hours.

Indications for use

• Reduced performance; mental and physical (including athletes) overload.

• As part of complex therapy: ischemic heart disease (exertional angina), chronic heart failure, cardialgia against the background of dyshormonal myocardial dystrophy.

• As part of complex therapy: cerebrovascular accident (ischemic stroke, chronic cerebrovascular insufficiency).

• Withdrawal symptoms in chronic alcoholism (as part of complex specific therapy).

Contraindications

Hypersensitivity to the main and / or auxiliary components of the drug; increased intracranial pressure (with impaired venous outflow and intracranial tumors); pregnancy; breastfeeding period; age up to 18 years (efficacy and safety have not been established).

Carefully

Chronic liver and / or kidney disease (due to insufficient data).

Application during pregnancy and during breastfeeding

The safety of use during pregnancy has not been proven. To avoid possible adverse effects on the fetus, the drug is not prescribed during pregnancy.

It is not known whether Meldonium is excreted in breast milk. If you need to use the drug CardionatЃ during lactation, you should stop breastfeeding.

Method of administration and dosage

Inside. The capsules should be swallowed whole, washed down with water.
In view of the possible development of an exciting effect, the drug is recommended to be used in the first half of the day.

Reduced performance, mental and physical overload - 500 mg (2 capsules) 2 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2 - 3 weeks.

Athletes - 500 mg - 1.0 g (2 - 4 capsules) 2 times a day before training. The duration of the course in the preparatory period of training is 14 - 21 days, during the competition period - 10 - 14 days.

Ischemic heart disease (exertional angina), chronic heart failure - 500 mg - 1.0 g (2 - 4 capsules) per day, using the entire dose at once or dividing it into 2 doses. The course of treatment is 4-6 weeks.

Cardialgia with dyshormonal myocardial dystrophy - 250 mg 2 times a day. The course of treatment is 12 days.

Cerebral circulation disorder.
In case of ischemic stroke - after the end of the 10-day course of therapy with the injectable form of CardionatЃ, the patient is transferred to taking the drug orally in capsules of 500 mg - 1.0 g (2 - 4 capsules) per day, taking the entire dose at once or dividing it into 2 doses. The general course of treatment is 4-6 weeks. For chronic cerebrovascular insufficiency - 500 mg (2 capsules) per day. The course of treatment is 2 - 3 weeks. The need for repeated courses of treatment (2-3 times a year) is determined by the doctor.

Withdrawal symptoms in chronic alcoholism - 500 mg (2 capsules) 4 times a day. The course of treatment is 7-10 days.

Side effect

On the part of the cardiovascular system : tachycardia, decrease or increase in blood pressure.

From the gastrointestinal tract : dyspeptic symptoms.

From the side of the central nervous system : excitement.

Allergic reactions : redness and itching of the skin, rash, swelling.

Others : eosinophilia, general weakness.

Overdose

Symptoms : a decrease in blood pressure, accompanied by headache, tachycardia, dizziness, general weakness.
Treatment is symptomatic.

Interaction with other medicinal products

Can be combined with antianginal drugs, anticoagulants, antiplatelet agents. antiarrhythmic drugs and drugs, etc. diure geek and. bronchodilators. Strengthens the effect of coronary dilating, some antihypertensive drugs, cardiac glycosides. When used together with nitroglycerin, nifedipine, alpha-blockers. other antihypertensive drugs and drugs and peripheral vasodilators should be used with caution in view of the possible development of moderate tachycardia and arterial hypotension.

special instructions

When treating patients with chronic liver and kidney diseases, caution should be exercised, especially with prolonged use of the drug.
Insufficient data on the use in children.

Influence on the ability to drive vehicles and mechanisms
There is no data on the adverse effect of CardionatЃ on the ability to drive vehicles and mechanisms.

Release form

250 mg capsules.
10 capsules in a blister strip made of polyvinyl chloride film and aluminum foil. 100 capsules in polymer jars for medicines, sealed with lids.
A polymer can or 2, 4 or 10 blisters together with instructions for use in a cardboard box.

Storage conditions

In a dry place at a temperature not exceeding 25 ? C.
Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date printed on the package.

Vacation conditions

On prescription.